On Monday, Standard BioTools Inc (NASDAQ: LAB) opened lower -5.30% from the last session, before settling in for the closing price of $1.32. Price fluctuations for LAB have ranged from $0.92 to $2.41 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 11.61% over the last five years. Company’s average yearly earnings per share was noted 55.47% at the time writing. With a float of $367.76 million, this company’s outstanding shares have now reached $379.09 million.
The firm has a total of 818 workers. Let’s measure their productivity. In terms of profitability, gross margin is 47.04%, operating margin of -82.21%, and the pretax margin is -78.07%.
Standard BioTools Inc (LAB) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Medical Devices industry is another important factor to consider. The insider ownership of Standard BioTools Inc is 3.18%, while institutional ownership is 72.23%. The most recent insider transaction that took place on May 23 ’25, was worth 1,344. In this transaction Chief Financial Officer of this company sold 1,428 shares at a rate of $0.94, taking the stock ownership to the 930,286 shares. Before that another transaction happened on May 23 ’25, when Company’s SVP & Chief Business Officer sold 13,217 for $0.94, making the entire transaction worth $12,437. This insider now owns 843,076 shares in total.
Standard BioTools Inc (LAB) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 55.47% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 66.44% during the next five years compared to 11.61% growth over the previous five years of trading.
Standard BioTools Inc (NASDAQ: LAB) Trading Performance Indicators
Check out the current performance indicators for Standard BioTools Inc (LAB). In the past quarter, the stock posted a quick ratio of 5.37. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.80.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.36, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach -0.15 in one year’s time.
Technical Analysis of Standard BioTools Inc (LAB)
Analysing the last 5-days average volume posted by the [Standard BioTools Inc, LAB], we can find that recorded value of 1.8 million was lower than the volume posted last year of 1.83 million. As of the previous 9 days, the stock’s Stochastic %D was 60.26%.
During the past 100 days, Standard BioTools Inc’s (LAB) raw stochastic average was set at 49.25%, which indicates a significant increase from 38.46% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0893 in the past 14 days, which was lower than the 0.0896 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1303, while its 200-day Moving Average is $1.4678. Now, the first resistance to watch is $1.2950. This is followed by the second major resistance level at $1.3400. The third major resistance level sits at $1.3650. If the price goes on to break the first support level at $1.2250, it is likely to go to the next support level at $1.2000. Now, if the price goes above the second support level, the third support stands at $1.1550.
Standard BioTools Inc (NASDAQ: LAB) Key Stats
There are currently 379,822K shares outstanding in the company with a market cap of 474.78 million. Presently, the company’s annual sales total 174,430 K according to its annual income of -138,890 K. Last quarter, the company’s sales amounted to 40,800 K and its income totaled -26,030 K.
